Head-to-head evidence
MET-097i vs ZT006
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
MET-097i
Developed by Pfizer
NCT06712836 · Phase 2 · completed
The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2027 · NCT07508241 (registry estimate)
ZT006
Developed by Beijing QL Biopharmaceutical
NCT07307638 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse-event rates rather than a weight-loss outcome, and no results have been posted yet, so its effect on body weight is unknown.
Next expected readout: December 2026 · NCT07230132 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MET-097i's landscape · ZT006's landscape